| 000 | 01765 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250512001241.0 | ||
| 264 | 0 | _c19860808 | |
| 008 | 198608s 0 0 eng d | ||
| 022 | _a0251-1649 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLuisetti, M | |
| 245 | 0 | 0 |
_aAmbroxol and pulmonary toxicity induced by antineoplastic drugs. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology research _c1986 |
||
| 300 |
_a129-36 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAmbroxol _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBleomycin _xadverse effects |
| 650 | 0 | 4 |
_aBromhexine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aBusulfan _xadverse effects |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Diseases _xchemically induced |
| 650 | 0 | 4 |
_aLymphocytes _ximmunology |
| 650 | 0 | 4 |
_aMacrophages _ximmunology |
| 650 | 0 | 4 |
_aMethotrexate _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutrophils _ximmunology |
| 650 | 0 | 4 |
_aNitrosourea Compounds _xadverse effects |
| 650 | 0 | 4 |
_aPhosphatidylcholines _xanalysis |
| 650 | 0 | 4 |
_aProcarbazine _xadverse effects |
| 650 | 0 | 4 |
_aPulmonary Alveoli _xanalysis |
| 650 | 0 | 4 |
_aPulmonary Fibrosis _xchemically induced |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRespiratory Function Tests |
| 700 | 1 | _aPeona, V | |
| 700 | 1 | _aSalmona, M | |
| 700 | 1 | _aPagnoni, A M | |
| 700 | 1 | _aVillani, F | |
| 700 | 1 | _aKnerich, R | |
| 700 | 1 | _aGenghini, M | |
| 700 | 1 | _aAbbà, L | |
| 700 | 1 | _aPozzi, E | |
| 773 | 0 |
_tInternational journal of clinical pharmacology research _gvol. 6 _gno. 2 _gp. 129-36 |
|
| 999 |
_c2430904 _d2430904 |
||